Inventor · disambiguated record
Krit Ritthipichai
Also filed as: RITTHIPICHAI KRIT
8 granted patents·9 pending applications·57 citations·filing 2018–2024
85Inventor score
Files withIOVANCE BIOTHERAPEUTICS INC17
Top patents by PatentIndex Score
17 records- 0197US11357841B2Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Granted Jun 14, 2022·24 cites·17 claims
- 0296US11713446B2Processes for generating TIL products enriched for tumor antigen-specific T-cellsIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Aug 1, 2023·18 cites·26 claims
- 0396US11384337B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2021·Granted Jul 12, 2022·7 cites·28 claims
- 0494US12031157B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Jul 9, 2024·2 cites·30 claims
- 0594US12024718B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Jul 2, 2024·2 cites·30 claims
- 0693US12495791B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Dec 16, 2025·1 cites·30 claims
- 0787US12104172B2Processes for generating TIL products enriched for tumor antigen-specific t-cellsIOVANCE BIOTHERAPEUTICS INC·Filed 2019·Granted Oct 1, 2024·3 cites·13 claims
- 0881US11866688B2Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Granted Jan 9, 2024·0 cites·9 claims
- 0979US2025223371A1Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonistsIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1075US2025066730A1Processes for generating til products enriched for tumor antigen-specific t-cellsIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1173US2021130779A1Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1268US2023210966A1Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1367US2021187029A1Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonistsIOVANCE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1457US2024269180A1Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1555US2022389381A1Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1655US2025345364A1Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapyIOVANCE BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1754US2020121719A1Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonistsIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Krit Ritthipichai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →